Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
NCT ID: NCT07049575
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
24 participants
INTERVENTIONAL
2025-11-15
2026-12-09
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ruxolitinib 1.5 % Cream
Participants received ruxolitinib 1.5% cream, applied topically to the affected area as defined in the protocol.
Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ruxolitinib Cream
Ruxolitinib cream applied topically to the affected area as a thin film twice daily.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
* Total estimated treatment BSA \> 20% at screening and baseline.
* Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
* Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
Exclusion Criteria
* Laboratory values outside of the protocol-defined ranges.
12 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Incyte Medical Monitor
Role: STUDY_DIRECTOR
Incyte Corporation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Saguaro Dermatology
Phoenix, Arizona, United States
First Oc Dermatology
Fountain Valley, California, United States
Amicis Research Center Valencia
Northridge, California, United States
Clinical Trials Research Institute
Thousand Oaks, California, United States
Clarity Dermatology
Castle Rock, Colorado, United States
International Clinical Research Tennessee Llc
Sanford, Florida, United States
Lenus Research Medical Group, Llc
Sweetwater, Florida, United States
Trueblue Clinical Research
Tampa, Florida, United States
Lane Dermatology and Dermatologic Surgery
Columbus, Georgia, United States
Equity Medical, Llc
Bowling Green, Kentucky, United States
Delricht Research
Baton Rouge, Louisiana, United States
Revival Research Institute, Llc Troy
Troy, Michigan, United States
Red River Research Partners
Bolivar, Missouri, United States
Dr Bobby Buka, Md Greenwich Village
New York, New York, United States
Equity Medical, Llc
New York, New York, United States
Red River Research Partners
Fargo, North Dakota, United States
Centricity Research Columbus Ohio Multispecialty Office
Columbus, Ohio, United States
Unity Clinical Research
Oklahoma City, Oklahoma, United States
Paddington Testing Co Inc
Philadelphia, Pennsylvania, United States
Dermresearch, Inc.
Austin, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Related Links
Access external resources that provide additional context or updates about the study.
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
INCB018424-112
Identifier Type: -
Identifier Source: org_study_id